Clinical Trials Logo
  1. Home
  2. Chemotherapy
  3. NCT05805800

Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

Chemotherapy-induced Nausea and Vomiting Clinical Trial

Official title:
Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent Nausea and Vomiting Induced by Chemotherapy：:A Non-inferiority, Prospective, Multi-Centered, Randomized, Controlled, Phase III Clinical Trial

Clinical Trial Summary

Nausea and vomiting caused by chemotherapy are considered by patients as the main side effects of cancer treatment, which affect the quality of treatment and life.At present, NCCN guidelines have recommended three or four drug regimens for highly emetic chemotherapy (HEC) to prevent vomiting, all containing dexamethasone.However, its side effects such as moderate to severe insomnia, hyperglycemia, dyspepsia, upper abdominal discomfort, irritability, increased appetite, weight gain and acne are gathering increasing concerns.For certain patients, the use of dexamethasone should be avoided.Analysis shows that olanzapine can replace the effect of dexamethasone.Hence, the investigators initiated this prospective, multi-center, phase III study to validate the dexamethasone-free protocol: removing dexamethasone from a three drug regimen containing olanzapine, dexamethasone, and 5-HT3RA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05805800
Study type Interventional
Source West China Hospital
Contact
Status Recruiting
Phase Phase 3
Start date March 15, 2023
Completion date March 15, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04054193 - Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) Phase 4
Recruiting NCT04430361 - the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Phase 2
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Completed NCT02285647 - An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant Phase 1
Terminated NCT01874119 - Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma Phase 2
Completed NCT01757210 - A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients N/A
Completed NCT01442376 - Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Phase 3
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Completed NCT01031498 - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Phase 2
Terminated NCT02519842 - Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) Phase 3
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT02909478 - Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Phase 3
Terminated NCT03237611 - Low Dose Aprepitant for Patients Receiving Carboplatin Phase 2
Completed NCT03649230 - Observational Study on the Use of Akynzeo® in Patients Receiving HEC
Not yet recruiting NCT02933099 - Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Phase 3
Completed NCT02557035 - An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting Phase 3
Completed NCT00787566 - Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting Phase 2
Completed NCT06121414 - Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy N/A
Completed NCT04918069 - Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN) Phase 2
Completed NCT05851625 - Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients N/A